Immutep Ltd
ASX:IMM
Intrinsic Value
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. [ Read More ]
The intrinsic value of one IMM stock under the Base Case scenario is 2.26 AUD. Compared to the current market price of 0.42 AUD, Immutep Ltd is Undervalued by 81%.
Valuation Backtest
Immutep Ltd
Run backtest to discover the historical profit from buying and selling IMM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Immutep Ltd
Current Assets | 113m |
Cash & Short-Term Investments | 103.7m |
Receivables | 6.1m |
Other Current Assets | 3.2m |
Non-Current Assets | 10.8m |
PP&E | 795.5k |
Intangibles | 8.7m |
Other Non-Current Assets | 1.2m |
Current Liabilities | 6.6m |
Accounts Payable | 3m |
Accrued Liabilities | 472.8k |
Other Current Liabilities | 3.1m |
Non-Current Liabilities | 1.6m |
Long-Term Debt | 1.4m |
Other Non-Current Liabilities | 184.5k |
Earnings Waterfall
Immutep Ltd
Revenue
|
256.6k
AUD
|
Operating Expenses
|
-47.2m
AUD
|
Operating Income
|
-46.9m
AUD
|
Other Expenses
|
6.4m
AUD
|
Net Income
|
-40.5m
AUD
|
Free Cash Flow Analysis
Immutep Ltd
IMM Profitability Score
Profitability Due Diligence
Immutep Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Immutep Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
IMM Solvency Score
Solvency Due Diligence
Immutep Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Immutep Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMM Price Targets Summary
Immutep Ltd
According to Wall Street analysts, the average 1-year price target for IMM is 1.28 AUD with a low forecast of 0.66 AUD and a high forecast of 2.84 AUD.
Shareholder Return
IMM Price
Immutep Ltd
Average Annual Return | -13.72% |
Standard Deviation of Annual Returns | 67.24% |
Max Drawdown | -99% |
Market Capitalization | 499.3m AUD |
Shares Outstanding | 1 188 829 952 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.
Contact
IPO
Employees
Officers
The intrinsic value of one IMM stock under the Base Case scenario is 2.26 AUD.
Compared to the current market price of 0.42 AUD, Immutep Ltd is Undervalued by 81%.